US20120289707A1 - Process for the preparation of amides - Google Patents

Process for the preparation of amides Download PDF

Info

Publication number
US20120289707A1
US20120289707A1 US13/556,904 US201213556904A US2012289707A1 US 20120289707 A1 US20120289707 A1 US 20120289707A1 US 201213556904 A US201213556904 A US 201213556904A US 2012289707 A1 US2012289707 A1 US 2012289707A1
Authority
US
United States
Prior art keywords
alkyl
hydrogen
independently
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/556,904
Inventor
Martin Charles Bowden
David Anthony Jackson
Alexandre Christian Saint-Dizier
George Robert Hodges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Crop Protection LLC
Original Assignee
Syngenta Crop Protection LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0808772A external-priority patent/GB0808772D0/en
Priority claimed from GB0808766A external-priority patent/GB0808766D0/en
Application filed by Syngenta Crop Protection LLC filed Critical Syngenta Crop Protection LLC
Priority to US13/556,904 priority Critical patent/US20120289707A1/en
Publication of US20120289707A1 publication Critical patent/US20120289707A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention relates to a process for the preparation of fungicidally active compounds such as tricyclic amine derivatives (I). The process involves coupling of a carboxylic acid e.g. a compound of formula (II) with an aniline, e.g. a compound of formula (III) in the presence of a boronic acid catalyst or an antimony catalyst
Figure US20120289707A1-20121115-C00001
wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Het are defined in the specification.

Description

  • The present invention relates to a process for the preparation of certain fungicidally active tricyclic amine derivatives and to certain fungicidally active ortho-substituted-cyclopropyl-azolcarboxamides.
  • Tricyclic amine derivatives having fungicidal activity are disclosed in WO/2004/035589 and WO 2007/048556. Ortho-substituted-cyclopropyl-azolcarboxamides of the formula (IA) are disclosed in WO03/074491
  • Figure US20120289707A1-20121115-C00002
  • wherein
    Heta is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by groups R4a, R5a and R6a;
    R1a is hydrogen or halo;
    R2a is hydrogen or halo;
    R3a is optionally substituted C2-12 alkyl, optionally substituted C2-12 alkenyl, optionally substituted C2-12 alkynyl, optionally substituted C3-12 cycloalkyl, optionally substituted phenyl or optionally substituted heterocyclyl; and
    R4a, R5a and R6a are independently selected from hydrogen, halo, cyano, nitro, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy(C1-4) alkyl and C1-4 haloalkoxy(C1-4) alkyl, provided that at least one of R4a, R5a and R6a is not hydrogen.
  • The compounds disclosed in WO03/074491 have microbiocidal activity, in particular fungicidal activity.
  • A variety of methods for the preparation of the above compounds have been described in WO2004/035589, WO 2007/048556, and WO 2003/074491.
  • It has now been surprisingly found that these compounds may be advantageously obtained by coupling the respective amine and carboxylic acid in the presence of a boronic acid catalyst or an antimony catalyst.
  • The present invention relates to a process for the preparation of compounds of the formula (I)
  • Figure US20120289707A1-20121115-C00003
  • wherein
    where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, provided that the ring is not 1,2,3-triazole, the ring being substituted by groups R8, R9 and R10;
    X is a single or double bond;
    Y is O, S, N(R11), (CR12R13)(CR14R15)m(CR16R17)n or C═C(A)Z in which A and Z are independently C1-6 alkyl or halogen;
    m is 0 or 1; n is 0 or 1;
    R1 is hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, CH2C≡CR18, CH2CR19═CHR20, CH═C═CH2 or COR21;
    R2 and R3 are each, independently, hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy or C1-4 haloalkoxy;
    R4, R5, R6 and R7 are each, independently, hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, hydroxymethyl, C1-4 alkoxymethyl, C(O)CH3 or C(O)OCH3;
    R8, R9 and R10 are each, independently, hydrogen, halogen, cyano, nitro, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy(C1-4)alkylene or C1-4 haloalkoxy(C1-4)alkylene, provided that at least one of R8, R9 and R10 is not hydrogen;
    R11 is hydrogen, C1-4 alkyl, benzyl (in which the phenyl group is optionally substituted with up to three substituents, each independently selected from halogen, C1-4 alkyl, C1-4 haloalkyl and C1-4 alkoxy), formyl, C(O)C1-4 alkyl (optionally substituted by halogen or C1-4 alkoxy), C(═O)O—C1-6 alkyl (optionally substituted by halogen, C1-4 alkoxy or cyano) or C1-4 alkoxy (C1-4) alkylene;
    R12, R13, R14, R15, R16 and R17 are each, independently, hydrogen, halogen, in hydroxy, C1-6 alkyl, C2-6 alkenyl [both optionally substituted by halogen, hydroxy, C1-4 alkoxy, ═O, aryl or O—C(O)—C1-4 alkyl or a 3-7 membered carboxylic ring (itself optionally substituted by up to three methyl groups)], a 3-7 membered saturated ring (optionally substituted by up to three methyl groups and optionally containing one heteroatom selected from nitrogen and oxygen) or C1-4 alkoxy; or R12 and R13 together with the carbon atom to which they are attached form the group C═O or a 3-5 membered carbocyclic ring (optionally substituted by up to three methyl groups and optionally with up to 2 heteroatoms each independently selected from O and N); or R12 and R13 together form a C1-6 alkylidene (optionally substituted by up to three methyl groups) or a C3-6 cycloalkylidene group (optionally substituted by up to three methyl groups);
    R18, R19 and R20 are each, independently, hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl or C1-4 alkoxy(C1-4)alkylene; and
    R21 is hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-4 alkoxy (C1-4) alkylene, C1-4 alkyl-S—(C1-4) alkylene, C1-4 alkoxy or aryl;
    comprising the step of reacting a carboxylic acid of formula (II)
  • Figure US20120289707A1-20121115-C00004
  • wherein Het is as defined above
    with an aniline of the formula (III)
  • Figure US20120289707A1-20121115-C00005
  • wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined above;
    in the presence of a boronic acid catalyst or an antimony catalyst.
  • Halogen is fluoro, chloro, bromo or iodo; preferably fluoro, chloro or bromo.
  • Each alkyl moiety is a straight or branched chain and is, for example, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, iso-propyl, sec-butyl, iso-butyl, tert-butyl, neo-pentyl, n-heptyl, 1,3-dimethylbutyl, 1,3-dimethylpentyl,1-methyl-3-ethyl-butyl or 1,3,3-trimethylbutyl. Likewise, each alkylene moiety is a straight or branched chain.
  • Haloalkyl moieties are alkyl moieties which are substituted by one or more of the same or different halogen atoms and are, for example, CF3, CF2Cl, CHF2, CH2F, CCl3, CF3CH2, CHF2CH2, CH2FCH2, CH3CHF or CH3CF2.
  • Alkenyl and alkynyl moieties can be in the form of straight or branched chains.
  • Each alkenyl moiety, where appropriate, may be of either the (E)- or (Z)-configuration.
  • A 3-5 membered carbocyclic ring includes a spiro-three or five membered ring.
  • Aryl includes phenyl, naphthyl, anthracyl, fluorenyl and indanyl but is preferably phenyl.
  • Alkyliden moieties may be in the form of straight or branched chains. Alkyliden includes methylidene[CH2═], ethylidene [CH3C(H)═], n-propylidene, i-propylidene [(CH3)2C═], n-butylidene, i-butylidene, 2-butylidene, n-pentylidene, i-pentylidene, neo-pentylidene, 2-pentylidene, n-hexylidene, 2-hexylidene, 3-hexylidene, i-hexylidene and neo-hexylidene.
  • Cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
  • Cycloalkenyl includes cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl.
  • Cycloalkylidene includes cyclopropylidene [c(C3H4)═], cyclobutylidene, cyclopentylidene and cyclohexylidene.
  • In one aspect of the invention, R11 is hydrogen, C1-4 alkyl, benzyl (in which the phenyl group is optionally substituted with up to three substituents, each independently selected from halogen, C1-4 alkyl, C1-4 haloalkyl and C1-4 alkoxy), formyl, C(O)C1-4 alkyl or C1-4 alkoxy (C1-4) alkylene.
  • In another aspect of the invention, R12, R13, R14, R15, R16 and R17 are each, independently, hydrogen, C1-4 alkyl or C1-4 alkoxy.
  • Het is preferably pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, pyridinyl, pyrimidyl, pyridazinyl, 2,3-hydro-[1, 4] oxathiine-6-yl, oxazinyl, thiazinyl or triazinyl.
  • Het is more preferably pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, pyridinyl or 2,3-dihydro-[1, 4] oxathiine-yl.
  • Het is even more preferably pyrrolyl, pyrazolyl, thiazolyl or pyridinyl.
  • Het is most preferably pyrrolyl or pyrazolyl.
  • Preferably X is a single bond.
  • In one aspect, Y is O, S, N(R11), CH2, CH2CH2, CH2CH2CH2, C(CH3)2, CH(CH3), CH C2H5), C(CH3)(C2H5), CH(OCH3) or C(OCH3)2; more preferably N(R11), O, S, CH2, CH2CH2, CH2CH2CH2, C(CH3)2, CH(CH3) or CH(C2H5); even more preferably N(R11), O, S, CH2 or CH2CH2; and still more preferably O, CH2 or N(R11). Preferably Y is O, N(R11) or (CR12R13)(CR14R15)m(CR16R17)n. More preferably Y is O or (CR12R13)(CR14R15)m(CR16R17)n. Even more preferably Y is (CR12R13)(CR14R15)m(CR16R17)n. Still more preferably Y is (CR12R13), e.g. CHCH(CH3)CH3.
  • In a further aspect, Y is C═C(A)Z in which A and Z are independently C1-6 alkyl or halogen. Preferably A and Z are independently halogen, more preferably both A and Z are chlorine.
  • Preferably n is 0.
  • Preferably m is 0.
  • Preferably R1 is hydrogen, CH2C≡CR18, CH═C═CH2 or COR21.
  • More preferably R1 is hydrogen, CH2C≡CH, CH═C═CH2, C(O)H or C(O)CH3.
  • Yet more preferably R1 is hydrogen, CH2C≡CH, CH═C═CH2 or C(O)CH3.
  • Even more preferably R1 is hydrogen, CH2C≡CH or CH═C═CH2.
  • Most preferably R1 is hydrogen.
  • Preferably R2 is hydrogen, halogen or C1-4 alkyl.
  • More preferably R2 is hydrogen or halogen.
  • Most preferably R2 is hydrogen.
  • Preferably R3 is hydrogen or methyl.
  • More preferably R3 is hydrogen.
  • Preferably R4 is hydrogen, C1-4 alkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C(O)CH3 or C(O)OCH3.
  • More preferably R4 is hydrogen, C1-2 alkyl, halogen, CF3, methoxy, C(O)CH3 or C(O)OCH3.
  • Even more preferably R4 is hydrogen, methyl, chlorine, CF3 or methoxy.
  • Most preferably R4 is hydrogen or methyl.
  • Preferably R5 is hydrogen, C1-4 alkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C(O)CH3 or C(O)OCH3.
  • More preferably R5 is hydrogen, C1-2 alkyl, chlorine, CF3, methoxy, C(O)CH3 or C(O)OCH3.
  • Most preferably R5 is hydrogen or methyl.
  • Preferably R6 is hydrogen, C1-4 alkyl, C1-4 alkoxy or C(O)CH3.
  • More preferably R6 is hydrogen, methyl, methoxy or C(O)CH3.
  • Most preferably R6 is hydrogen or methyl.
  • Preferably R7 is hydrogen, C1-4 alkyl, C1-4 alkoxy or C(O)CH3.
  • More preferably R7 is hydrogen, methyl, methoxy or C(O)CH3.
  • Most preferably R7 is hydrogen or methyl.
  • Preferably R8 is hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl or methoxymethylene.
  • More preferably R8 is hydrogen, chloro, fluoro, bromo, C1-2 alkyl, CF3, CF2Cl, CHF2, CH2F or methoxymethylene.
  • Even more preferably R8 is hydrogen, chloro, fluoro, C1-2 alkyl, CF3, CF2Cl, CHF2, CH2F or methoxymethylene.
  • Most preferably R8 is hydrogen, chloro, fluoro, methyl, CF3, CHF2 or CH2F.
  • Preferably R9 is hydrogen, halogen, C1-4 alkyl or C1-4 haloalkyl or methoxymethylene.
  • More preferably R9 is hydrogen, chloro, fluoro, bromo, C1-2 alkyl, CF3, CF2Cl, CHF2, CH2F or methoxymethylene.
  • Even more preferably R9 is hydrogen, chloro, fluoro, C1-2 alkyl, CF3, CF2Cl, CHF2, CH2F or methoxymethylene.
  • Most preferably R9 is hydrogen, chloro, fluoro, methyl, CF3, CHF2 or CH2F.
  • Preferably R10 is hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl or methoxymethylene.
  • More preferably R10 is hydrogen, chloro, fluoro, bromo, C1-2 alkyl, CF3, CF2Cl, CHF2, CH2F or methoxymethylene.
  • Even more preferably R10 is hydrogen, chloro, fluoro, C1-2 alkyl, CF3, CF2Cl, CHF2, CH2F or methoxymethylene.
  • Most preferably R10 is hydrogen, chloro, fluoro, methyl, CF3, CHF2 or CH2F.
  • In one aspect of the invention R11 is hydrogen, C1-4 alkyl, benzyl, formyl, C(O)CH3 or C(O)OC(CH3)3; more preferably hydrogen or C1-2 alkyl.
  • Preferably R11 is C1-4 alkyl, formyl, C(O)CH3 or C(O)OC1-6 alkyl (optionally substituted by halogen, CN or C1-4 alkoxy).
  • More preferably R11 is C(O)OC1-4 alkyl.
  • In one aspect of the invention R12, R13, R14, R15, R16 and R17 are each, independently, hydrogen, C1-2 alkyl or methoxy.
  • Preferably R12 and R13 are each, independently, hydrogen, halogen, C1-5 alkyl, C1-3 alkoxy, CH2OH, CH(O), C3-6 cycloalkyl, CH2O—C(═O)CH3, CH2—C3-6 cycloalkyl or benzyl; or R12 and R13 together with the carbon atom to which they are attached form the group C═O or a 3-5 membered carbocyclic ring; or R12 and R13 together form C1-5 alkylidene or C3-6 cycloalkylidene.
  • More preferably R12 and R13 are, independently, H, CH3, C2H5, n-C3H7, i-C3H7, n-C4H9, sec-C4H9, i-C4H9, CH(C2H5)2, CH2-cyclopropyl or cyclopentyl; or R12 and R13 together with the carbon atom to which they are attached form a 3-membered or 5-membered carbocyclic ring.
  • Preferably R14 is H or CH3.
  • Preferably R15 is H or CH3.
  • Preferably R16 is H or CH3.
  • Preferably R17 is H or CH3.
  • Preferably R18 is hydrogen, chloro, bromo, methyl or methoxy.
  • More preferably R18 is hydrogen, chloro or methyl.
  • Most preferably R18 is hydrogen.
  • Preferably R19 is hydrogen, chloro, bromo, methyl or methoxy.
  • More preferably R19 is hydrogen, chloro or methyl.
  • Most preferably R19 is hydrogen.
  • Preferably R20 is hydrogen, chloro, bromo, methyl or methoxy.
  • More preferably R20 is hydrogen, chloro or methyl.
  • Most preferably R20 is hydrogen.
  • Preferably R21 is hydrogen, methyl, OC(CH3)3 or CH3OCH2.
  • For example,
  • Het is pyrrolyl or pyrazolyl, either being substituted by groups R8, R9 and R10;
  • X is a single bond;
  • Y is (CR12R13)(CR14R15)m(CR16R17)n or C═C(A)Z in which A and Z are independently C1-6 alkyl or halogen;
  • m is 0 or 1;
  • n is 0 or 1;
  • R1 is hydrogen;
  • R2 and R3 are each, independently, hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy or C1-4 haloalkoxy;
  • R4, R5, R6 and R7 are each, independently, hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, hydroxymethyl, C1-4 alkoxymethyl, C(O)CH3 or C(O)OCH3;
  • R8, R9 and R10 are each, independently, hydrogen, halogen, cyano, nitro, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy(C1-4)alkylene or C1-4 haloalkoxy(C1-4)alkylene, provided that at least one of R8, R9 and R10 is not hydrogen;
  • R12 and R13 are each, independently, hydrogen, halogen, C1-5 alkyl, C1-3 alkoxy, CH2OH, CH(O), C3-6 cycloalkyl, CH2O—C(═O)CH3, CH2—C3-6 cycloalkyl or benzyl; or R12 and R13 together with the carbon atom to which they are attached form the group C═O or a 3-5 membered carbocyclic ring;
  • or R12 and R13 together form C1-5 alkylidene or C3-6 cycloalkylidene; and
  • R14, R15, R16 and R17 are each, independently, H or CH3.
  • Preferably, R8, R9 and R10 are each, independently, hydrogen, chloro, fluoro, methyl, CF3, CHF2 or CH2F, provided that at least one of R8, R9 and R10 is not hydrogen.
  • Preferably, n is 0 and m is 0. Preferably, R12 and R13 are each, independently, hydrogen, C1-4 alkyl or C1-4 alkoxy. Preferably, R2 is hydrogen, halogen or C1-4 alkyl.
  • Preferably, R3 is hydrogen or methyl. Preferably Het is pyrazolyl.
  • Preferably Het is a group of formula (VIIA)
  • Figure US20120289707A1-20121115-C00006
  • in which R7a is selected from CF3 and CHF2;
  • Preferably, R1, R2, R3, R4, R5, R6, R7 are each independently hydrogen.
  • Preferably, X is a single bond;
  • Preferably, Y is C═CCl2 or CHCH(CH3)CH3.
  • For example, in one embodiment:
  • Het is a group of formula (VIIA)
  • Figure US20120289707A1-20121115-C00007
  • in which R7a is selected from CF3 and CHF2;
  • R1, R2, R3, R4, R5, R6, R7 are each independently hydrogen;
  • X is a single bond;
  • Y is CHCH(CH3)CH3; and the catalyst is a boronic acid catalyst or an antimony catalyst, e.g. boric acid or an aryl boronic acid such as 3,5-bis-(trifluoromethyl)-phenylboronic acid or 2-(N,N-dimethylaminomethyl)phenylboronic acid, or an antimony III alkoxide such as Sb(OEt)3. For example, the catalyst may be 3,5-bis-(trifluoromethyl)-phenylboronic acid or Sb(OEt)3.
  • For example, in further embodiment:
  • Het is a group of formula (VIIA)
  • Figure US20120289707A1-20121115-C00008
  • in which R7a is selected from CF3 and CHF2;
    R1, R2, R3, R4, R5, R6, R7 are each independently hydrogen;
    X is a single bond;
    Y is C═C(A)Z in which A and Z are, independently fluoro, chloro or bromo, preferably chloro;
    and the catalyst is a boronic acid catalyst or an antimony catalyst, e.g. boric acid or an aryl boronic acid such as 3,5-bis-(trifluoromethyl)-phenylboronic acid or 2-(N,N-dimethylaminomethyl)phenylboronic acid, or an antimony III alkoxide such as Sb(OEt)3. For example, the catalyst may be boric acid or 2-(N,N-dimethylaminomethyl)phenylboronic acid.
  • According to a very highly preferred embodiment, the invention relates to a process for the preparation of a compound of formula (VI)
  • Figure US20120289707A1-20121115-C00009
  • comprising reacting a carboxylic acid of formula (IV)
  • Figure US20120289707A1-20121115-C00010
  • with an aniline of formula (V)
  • Figure US20120289707A1-20121115-C00011
  • in the presence of a boronic acid catalyst or an antimony catalyst, e.g. boric acid or an aryl boronic acid such as 3,5-bis-(trifluoromethyl)-phenylboronic acid or 2-(N,N-dimethylaminomethyl)phenylboronic acid, or an antimony III alkoxide such as Sb(OEt)3. For example, the catalyst may be 3,5-bis-(trifluoromethyl)-phenylboronic acid or Sb(OEt)3.
  • According to a further highly preferred embodiment of the invention, the invention relates to a process for the preparation of a compound of formula (VIII)
  • Figure US20120289707A1-20121115-C00012
  • comprising reacting a carboxylic acid of formula (IV)
  • Figure US20120289707A1-20121115-C00013
  • with an aniline of formula (VII)
  • Figure US20120289707A1-20121115-C00014
  • in the presence of a boronic acid catalyst or an antimony catalyst, e.g. boric acid or an aryl boronic acid such as 3,5-bis-(trifluoromethyl)-phenylboronic acid or 2-(N,N-dimethylaminomethyl)phenylboronic acid, or an antimony III alkoxide such as Sb(OEt)3. For example, the catalyst may be boric acid or 2-(N,N-dimethylaminomethyl)phenylboronic acid.
  • In a further embodiment, the present invention provides a process for the preparation of compounds of formula (IA)
  • Figure US20120289707A1-20121115-C00015
  • wherein
    Heta is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by groups R4a, R5a and R6a;
    R1a is hydrogen or halogen;
    R2a is hydrogen or halogen;
    R3a is optionally substituted C2-12 alkyl, optionally substituted C2-12 alkenyl, optionally substituted C2-12 alkynyl, optionally substituted C3-12 cycloalkyl, optionally substituted phenyl or optionally substituted heterocyclyl; and
    R4a, R5a and R6a are independently selected from hydrogen, halogen, cyano, nitro, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy(C1-4) alkyl and C1-4 haloalkoxy(C1-4) alkyl, provided that at least one of R4a, R5a and R6a is not hydrogen
    comprising reacting a carboxylic acid of formula (IIA)
  • Figure US20120289707A1-20121115-C00016
  • with an aniline of the formula (IIIA)
  • Figure US20120289707A1-20121115-C00017
  • in the presence of a boronic acid catalyst or an antimony catalyst.
  • Halogen is fluoro, chloro or bromo.
  • Each alkyl moiety is a straight or branched chain and is, for example, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl or neo-pentyl.
  • When present, each optional substituent on an alkyl moiety is, independently, selected from halogen, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H); where R′ and R″ are, independently, hydrogen or C1-4 alkyl.
  • Alkenyl and alkynyl moieties can be in the form of straight or branched chains.
  • The alkenyl moieties, where appropriate, can be of either the (E)- or (Z)-configuration. Examples are vinyl, allyl and propargyl.
  • When present, each optional substituent on alkenyl or on alkynyl is, independently, selected from those optional substituents given above for an alkyl moiety.
  • Cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • When present, each optional substituent on cycloalkyl is, independently, selected from C1-3 alkyl and those optional substituents given above for an alkyl moiety.
  • The term heterocyclyl refers to a non-aromatic or aromatic ring containing up to 10 atoms including one or more (preferably one or two) heteroatoms selected, each independently, from O, S and N. Examples of such rings include 1,3-dioxolanyl, tetrahydrofuranyl, morpholinyl, thienyl and furyl.
  • When present, each optional substituent on phenyl or on heterocyclyl is, independently, selected from C1-6 alkyl and those optional substituents given above for an alkyl moiety. When present, there are up to four optional substituents on phenyl, each independently selected.
  • When present, each optional substituent on an alkyl moiety is, independently, selected from the preferred list of halo, hydroxy, methoxy, trifluoromethoxy, difluoromethoxy, cyano and nitro.
  • When present, each optional substituent on alkenyl or on alkynyl is, independently, selected from the preferred list of halogen and cyano.
  • When present, each optional substituent on cycloalkyl is, independently, selected from the preferred list of methyl, ethyl, trifluoromethyl, methoxy, trifluoromethoxy and cyano.
  • When present, each optional substituent on phenyl or on a heterocyclyl group is, independently, selected from the preferred list of halo, hydroxy, methoxy, trifluoromethoxy, difluoromethoxy and cyano.
  • It is preferred that Heta is pyrrolyl, pyrazolyl, thiazolyl, pyridinyl, pyrimidinyl, thiophenyl, furyl, isothiazolyl or isoxazolyl (more preferably pyrrolyl, pyrazolyl or thiazolyl), each being substituted by groups R4a, R5a and R6a.
  • Preferably
  • Heta is pyrrolyl, pyrazolyl or thiazolyl, each being substituted by groups R4a, R5a, R6a;
    R1a is hydrogen, fluoro, chloro or bromo;
    R2a is hydrogen, fluoro, chloro or bromo;
    R3a is optionally substituted C2-12 alkyl, wherein, when present, each optional substituent is, independently, selected from fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H); optionally substituted C2-12 alkenyl, wherein, when present, each optional substituent is, independently, selected from fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4-alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H); optionally substituted C2-12 alkynyl, wherein, when present, each optional substituent is, independently, selected from fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H); optionally substituted C3-12 cycloalkyl, wherein, when present, each optional substituent is, independently, selected from C1-3 alkyl, fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H); optionally substituted phenyl, wherein, when present, each optional substituent is, independently, selected from C1-6 alkyl, fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H); or optionally substituted heterocyclyl, wherein, when present, each optional substituent is, independently, selected from C1-6 alkyl, fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N; R′ and R″ are, independently, hydrogen or C1-4 alkyl; and
    R4a, R5a, and R6a are, independently, selected from hydrogen, fluoro, chloro, bromo, cyano, nitro, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy(C1-4)alkyl and C1-4 haloalkoxy(C1-4)alkyl, provided that at least one of R4a, R5a, and R6a is not hydrogen.
  • Preferably R1a and R2a are, independently, hydrogen or fluoro.
  • Preferably R3a is C2-6 alkyl, optionally substituted C3-8 cycloalkyl, phenyl, thienyl or furyl.
  • Preferably R4a, R5a and R6a are, independently, selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl and C1-4 alkoxy(C1-4)alkyl; provided that at least one of R4a, R5a and R6a is not hydrogen. More preferably R4a, R5a, and R6a are, independently, selected from hydrogen, halogen, methyl, C1-2 haloalkyl and methoxymethyl; provided that at least one of R4a, R5a and R6a is not hydrogen.
  • Preferably, Heta is pyrazolyl. More preferably, Heta is pyrazol-4-yl. More preferably, Heta is a group of formula (VIIA)
  • Figure US20120289707A1-20121115-C00018
  • wherein R7a is selected from CF3 and CHF2. Preferably, R7a is CHF2.
  • Preferably, R1a is hydrogen. Preferably, R2a is hydrogen. More preferably, R1a and R2a are hydrogen.
  • Preferably, R3a is optionally substituted cycloalkyl. More preferably, R3a is optionally substituted cyclopropyl. More preferably, R3a is a group of the formula (VIIIA)
  • Figure US20120289707A1-20121115-C00019
  • wherein R8a is H or C1-6 alkyl. Preferably, R8a is H or Methyl. More preferably, R8a is H.
  • For example,
  • Heta is a group of formula (VIIA)
  • Figure US20120289707A1-20121115-C00020
  • wherein R7a is selected from CF3 and CHF2;
    R1a is R2a, and R3a are hydrogen;
    R3a is a group of the formula (VIIIA)
  • Figure US20120289707A1-20121115-C00021
  • wherein R8a is H or C1-4 alkyl, preferably H or Methyl, more preferably H; and the catalyst is a boronic acid catalyst or an antimony catalyst, e.g. boric acid or an aryl boronic acid such as 3,5-bis-(trifluoromethyl)-phenylboronic acid or 2-(N,N-dimethylaminomethyl)phenylboronic acid, or an antimony III alkoxide such as Sb(OEt)3. For example, the catalyst may be boric acid or 2-(N,N-dimethylaminomethyl)phenylboronic acid.
  • According to a very highly preferred embodiment, the invention relates to a process for the preparation of a compound of formula (IXA)
  • Figure US20120289707A1-20121115-C00022
  • comprising reacting an acid of formula (XA)
  • Figure US20120289707A1-20121115-C00023
  • with an aniline of formula (XIA)
  • Figure US20120289707A1-20121115-C00024
  • in the presence of a boronic acid catalyst or an antimony catalyst, e.g. boric acid or an aryl boronic acid such as 3,5-bis-(trifluoromethyl)-phenylboronic acid or 2-(N,N-dimethylaminomethyl)phenylboronic acid, or an antimony III alkoxide such as Sb(OEt)3. For example, the catalyst may be boric acid or 2-(N,N-dimethylaminomethyl)phenylboronic acid.
    • Ratio of Reagents
  • Preferably, the molar ratio of acid (II) or (IIA):aniline (III) or (IIIA) is in the range of from 10:1 to 1:10. More preferably, the molar ratio of acid (II) or (IIA):aniline (III) or (IIIA) is in the range of from 5:1 to 1:5. More preferably, the molar ratio of acid (II) or (IIA):aniline (III) or (IIIA) is in the range of from 2:1 to 1:2. More preferably, the molar ratio of acid (II) or (IIA):aniline (III) or (IIIA) is in the range of from 1.2:1 to 1:1.2. More preferably, the molar ratio of acid (II) or (IIA):aniline (III) or (IIIA) is in the range of from 1.1:1 to 1:1.1.
    • Solvent
  • The reaction of the invention is optionally (and preferably) conducted in a suitable solvent. Suitable solvents include, but are not limited to, linear, branched or cyclic aliphatic hydrocarbons, such as ligroin or cyclohexane, pentane, hexane, heptane, octane, as well as aromatic solvents, such as benzene, toluene, xylene, monochlorobenzene, dichlorobenzene, trichlorobenzene.
  • A preferred solvent is xylene.
    • Temperature
  • The reaction of the invention may be carried out at a temperature such that an acceptable rate of reaction is attained. Preferably, the reaction is conducted at a temperature of from 0° C. to 200° C. More preferably, the reaction is conducted at a temperature of from 50° C. to 180° C. More preferably, the reaction is conducted at a temperature of from 100° C. to 170° C. More preferably, the reaction is conducted at a temperature of from 130° C. to 150° C.
    • Removal of Water
  • Preferably, provision is made for removal of water from the reaction mixture, e.g. removal of water prior to completion of the reaction. Water may be removed from the reaction continuously. A suitable method is azeotropic removal of water. Suitable apparatus for conducting azeotropic removal of water will be known to those skilled in the art. We have found that removal of water is highly desirable in order to achieve a commercially useful conversion to product.
    • Boronic Acid
  • Examples of the boronic acids include boric acid, phenylboronic acid, 2-methylphenylboronic acid, 3-methylphenylboronic acid, 4-methylphenylboronic acid, 2,3-dimethylphenylboronic acid, 4-dimethylphenylboronic acid, 2,5-dimethylphenylboronic acid, 2-ethylphenylboronic acid, 4-n-propylphenylboronic acid, 4-isopropylphenylboronic acid, 4-n-butylphenylboronic acid, 4-tert-butylphenylboronic acid, 1-naphthylboronic acid, 2-naphthylboronic acid, 2-biphenylboronic acid, 3-biphenylboronic acid, 4-biphenylboronic acid, 2-fluoro-4-biphenylboronic acid, 2-fluorenylboronic acid, 9-fluorenylboronic acid, 9-phenanthrenylboronic acid, 9-anthracenylboronic acid, 1-pyrenylboronic acid, 2-trifluoromethylphenylboronic acid, 3-trifluoromethylphenylboronic acid, 4-trifluorophenylboronic acid, 3,5-bis(trifluoromethyl)phenylboronic acid, 2-methoxyphenylboronic acid, 3-methoxyphenylboronic acid, 4-methoxyphenylboronic acid, 2,5-dimethoxyphenylboronic acid, 4,5-dimethoxyphenylboronic acid, 2,4-dimethoxyphenylboronic acid, 2-ethoxyphenylboronic acid, 3-ethoxyphenylboronic acid, 4-ethoxyphenylboronic acid, 4-phenoxyboronic acid, 4-methylenedioxyphenylboronic acid, 2-fluorophenylboronic acid, 3-fluorophenylboronic acid, 4-fluorophenylboronic acid, 2,4-difluorophenylboronic acid, 2,5-difluorophenylboronic acid, 4,5-difluorophenylboronic acid, 3,5-difluorophenylboronic acid, 2-formylphenylboronic acid, 3-formylphenylboronic acid, 4-formylphenylboronic acid, 3-formyl-4-methoxyphenylboronic acid, 2-cyanophenylboronic acid, 3-cyanophenylboronic acid, 4-cyanophenylboronic acid, 3-nitrophenylboronic acid, 3-acetylphenylboronic acid, 4-acetylphenylboronic acid, 3-trifluoroacetylphenylboronic acid, 4-trifluoroacetylphenylboronic acid, 4-methylthiophenylboronic acid, 4-vinylphenylboronic acid, 3-carboxyphenylboronic acid, 4-carboxyphenylboronic acid, 3-aminophenylboronic acid, 2-(N,N-dimethylamino)phenylboronic acid, 3-(N,N-dimethylamino)phenylboronic acid, 4-(N,N-dimethylamino)phenylboronic acid, 2-(N,N-diethylamino)phenylboronic acid, 3-(N,N-diethylamino)phenylboronic acid, 4-(N,N-diethylamino)phenylboronic acid, 2-(N,N-dimethylaminomethyl)phenylboronic acid, furan-2-boronic acid, furan-3-boronic acid, 4-formyl-2-furanboronic acid, dibenzofuran-4-boronic acid, benzofuran-2-boronic acid, thiophene-2-boronic acid, thiophene-3-boronic acid, 5-methylthiophene-2-boronic acid, 5-chlorothiophene-2-boronic acid, 4-methylthiophene-2-boronic acid, 5-methylthiophene-2-boronic acid, 2-acetylthiophene-5-boronic acid, 5-methylthiophene-2-boronic acid, benzothiophene-2-boronic acid, dibenzothiophene-4-boronic acid, pyridine-3-boronic acid, pyridine-4-boronic acid, pyrimidine-5-boronic acid, quinoline-8-boronic acid, isoquinoline-4-boronic acid, 4-benzenebis(boronic acid), phenylboronic acid-pinacol ester, and 4-cyanophenylboronic acid-pinacol ester.
  • A preferred class of boronic acids are aryl boronic acids. Most preferred is 2-(N,N-dimethylaminomethyl)phenylboronic acid and 3,5-trifluoromethylphenylboronic acid.
  • An alternative preferred boronic acid is boric acid.
    • Antimony
  • Antimony for use as a catalyst in the present invention may be, for example, antimony III or antimony V.
  • Examples of antimony for use as a catalyst include antimony complexes, e.g. organo antimony complexes such as aryl antimony complexes and saturated and unsaturated carbon chain antimony complexes, with the ligand complexed to the antimony with a suitable coordination atom, e.g. selected from O, S or N. Example of suitable antimony catalysts include:
  • antimony halides, e.g. SbCl3,
    antimony oxides, e.g. Sb2C3,
    antimony alkoxides, e.g. Sb(ORx)3 in which Rx is alkyl, alkenyl, alkynyl, e.g. C1-C4 alkyl, C2-C4 alkenyl, e.g. C3-C4 alkynyl, in particular Sb(OEt)3,
    antimony carboxylic acids, e.g. Sb(C2CRx)3 in which Rx is as defined above, in particular Sb(Ac)3.
  • Examples of antimony V catalysts include aryl antimony complexes, such as those mentioned in Nomura et al., Chemistry Letters, The Chemical Society of Japan, 1986, pages 1901-1904. These include antimony complexed with aryl groups and carboxylates, e.g. Ph3Sb(C2CRx)2 in which Rx is as defined above, particularly Ph3Sb(OAc)2, and antimony oxides complexed with aryl groups, e.g. Ph3SbO.
    • Catalyst Recycle
  • Preferably the catalyst is recycled, e.g. by extracting the catalyst from the reaction solution into the aqueous phase. Extraction of the catalyst may be achieved by changing the pH of the reaction solution, e.g. to alkaline pH, so that the catalyst transfers from the organic phase to the aqueous phase. The catalyst may subsequently be transferred from the aqueous phase to fresh reactant solution by changing the pH, e.g. to acidic pH.
  • Boronic acid catalysts, such as 3,5-bis-(trifluoromethyl)-phenylboronic acid, are particularly suitable for catalyst recycle by extracting the catalyst from the reactant solution to aqueous phase.
    • Amount of Catalyst
  • Preferably, the amount of catalyst employed is up to 50 mol % based on the amount of carboxylic acid (II) or (IIA). More preferably, the amount of catalyst employed is up to 25 mol % based on the amount of carboxylic acid (II) or (IIA). More preferably, the amount of catalyst employed is up to 15 mol % based on the amount of carboxylic acid (II) or (IIA).
  • Preferably, the amount of catalyst employed is at least 0.01 mol % based on the amount of carboxylic acid (II) or (IIA). More preferably, the amount of catalyst employed is at least 0.1 mol % based on the amount of carboxylic acid (II) or (IIA). More preferably, the amount of catalyst employed is at least 1 mol % based on the amount of carboxylic acid (II) or (IIA).
  • Preferably, the amount of catalyst employed is between 0.01 and 50 mol % based on the amount of carboxylic acid (II) or (IIA). More preferably, the amount of catalyst employed is between 0.1 and 25 mol % based on the amount of carboxylic acid (II) or (IIA). More preferably, the amount of catalyst employed is between 1 and 15 mol % based on the amount of carboxylic acid (II) or (IIA). More preferably, the amount of catalyst employed is between 8 and 12 mol % based on the amount of carboxylic acid (II) or (IIA).
  • Preferably, the amount of catalyst employed is up to 50 mol % based on the amount of aniline (III) or (IIIA). More preferably, the amount of catalyst employed is up to 25 mol % based on the amount of aniline (III) or (IIIA). More preferably, the amount of catalyst employed is up to 15 mol % based on the amount of aniline (III) or (IIIA).
  • Preferably, the amount of catalyst employed is at least 0.01 mol % based on the amount of aniline (III) or (IIIA). More preferably, the amount of catalyst employed is at least 0.1 mol % based on the amount of aniline (III) or (IIIA). More preferably, the amount of catalyst employed is at least 1 mol % based on the amount of aniline (III) or (IIIA).
  • Preferably, the amount of catalyst employed is between 0.01 and 50 mol % based on the amount of aniline (III) or (IIIA). More preferably, the amount of catalyst employed is between 0.1 and 25 mol % based on the amount of aniline (III) or (IIIA). More preferably, the amount of catalyst employed is between 1 and 15 mol % based on the amount of aniline (III) or (IIIA). More preferably, the amount of catalyst employed is between 8 and 12 mol % based on the amount of aniline (III) or (IIIA).
  • Usually one type of catalyst will be used in a reaction. However, the invention also covers reactions in which more than one type of catalyst is used, e.g. either separately, sequentially or simultaneously. For example, more than one type of boronic catalyst or antimony catalyst may be used or a boronic acid catalyst and an antimony catalyst may be used.
    • Synthesis of Starting Materials
  • Suitable methods for the preparation of carboxylic acids (II) and anilines (III) are disclosed in WO04/035589 and WO 2007/048556. Suitable methods for the preparation of carboxylic acids (IIA) and anilines (IIIA) are disclosed in WO03/074491. Other methods will be apparent to those skilled in the art.
    • Workup and Isolation of Products
  • Workup of the reaction mixture is achieved according to well known procedures of synthetic organic chemistry. For example, an aqueous workup may be achieved by the addition of water (or other aqueous solution), and extraction of the desired product with a suitable organic solvent.
  • Alternatively, the product may be isolated by removing any solvent present by distillation, e.g. under reduced pressure.
  • Purification of the product may be achieved by any one of a number of methods, e.g. distillation, recrystallization and chromatography.
  • The present invention will now be described by way of the following non-limiting examples. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques.
  • All references mentioned herein are incorporated by reference in their entirety. All aspects and preferred features of the invention may be combined with each other, except where this is evidently not possible.
  • FIG. 1
  • FIG. 1 shows the reaction profile of the boronic acid catalysed reaction of Example 2:
  • Figure US20120289707A1-20121115-C00025
  • using 10 mole % catalyst, under azeotropic reflux in toluene. The X axis indicates time in hours and the Y axis indicates mole fraction. Triangles represent the acid reactant, diamonds represent the aniline reactant, circles represent product.
  • FIG. 2
  • FIG. 2 shows a profile of mole fraction of 3,5-bis-(trifluoromethyl)-phenylboronic acid catalyst in the organic phase (toluene) versus pH. Circles represent modelled data, diamonds represent experimental data.
    •  EXAMPLES Example 1 Reaction Sequence (Absence of Catalyst)
  • Figure US20120289707A1-20121115-C00026
  • An oven-dried round bottomed flask was evacuated and refilled with nitrogen three times. The flask was fitted with a dropping funnel containing charged 3 Å molecular sieves, and this was connected to the nitrogen line. 3-Difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (0.36 g, 2 mmol), 9-Isopropyl-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-ylamine (0.4 g, 2 mmol) were added to the flask, followed by anhydrous toluene (2 mL) via syringe. The mixture was azeotropically refluxed overnight, under nitrogen. After this time, the solution was cooled and concentrated in vacuo to give a pale brown solid. 1H and 19F NMR and GC analyses showed only 5% conversion to amide product.
    • Example 2 Reaction Sequence
  • Figure US20120289707A1-20121115-C00027
  • An oven-dried flask was evacuated and refilled with nitrogen three times. The flask was fitted with a dropping funnel containing charged 3 Å molecular sieves. 3-Difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (0.36 g, 2 mmol), 9-Isopropyl-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-ylamine (0.4 g, 2 mmol) were added to the flask, followed by 3,5-bis-(trifluoromethyl)-phenylboronic acid (26 mg, 5 mol %) and anhydrous toluene (4 mL). The mixture was heated to reflux and was azeotropically refluxed overnight under nitrogen. A sample was analysed by GC which indicated quantitative conversion to the amide and so the solution was cooled, and quenched with saturated aqueous solutions of sodium hydrogencarbonate (10 mL) and ammonium chloride (10 mL).
  • The aqueous layer was extracted with ethyl acetate (3×10 mL). Combined organic extracts were washed with water (10 mL), dried with MgSC4 and concentrated in vacuo to give a brown solid which was identified as the amide product by 1H and 19F NMR, and GC-MS (0.55 g, 76%).
  • The boronic acid catalysed reaction was profiled using 10 mole % catalyst, under azeotropic reflux in toluene. The removal of water by azeotropic reflux appears to be advantageous, since without these conditions, reactions were not complete after 18 hours. See FIG. 1.
  • Recycling of the catalyst was by extracting the boronic acid from the reaction mass with strong aqueous alkali, acidifying and then re-extracting into toluene ready for the next batch was investigated. The phase partition was modelled using the calculated Log P (3.013) and pKa (6.57) and the experimental values are close although show a slight tail at the higher pH possibly due to the high ionic strength. See FIG. 2.
  • Catalyst recycle would significantly reduce the cost contribution of catalyst to the product.
    • Example 3 Reaction Sequence
  • Figure US20120289707A1-20121115-C00028
  • An oven-dried flask was evacuated and refilled with nitrogen three times. The flask was fitted with a dropping funnel containing charged 3 Å molecular sieves. 3-Difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (0.36 g, 2 mmol), 9-Isopropyl-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-ylamine (0.4 g, 2 mmol) were added to the flask, followed by antimony (III) ethoxide (34 μL, 5 mol %) and anhydrous toluene (4 mL). The reaction was refluxed azeotropically overnight, under an atmosphere of nitrogen. A sample was analysed by GC which indicated quantitative conversion to the amide and so the solution was quenched with methanol (5 mL), and a solid crashed out of the resulting solution. This suspension was filtered through a pad of Celite, washing with 50/50 ethyl acetate/acetone (10 mL). The resulting solution was concentrated in vacuo to yield a yellow solid which was identified by 1H and 19F NMR, and GCMS analyses as the amide product (0.53 g, 73%).
    • Example 4 Reaction Sequence
  • Figure US20120289707A1-20121115-C00029
  • Actual Strength 100% Mol Mol.
    Materials Wt (g) (%) Wt. (g) Wt. mmol. Ratio
    DF-Pyrazole 0.41 95.9 0.393 176 2.2 1.0
    acid (IV)
    Aniline (VII) 0.52 95 0.494 239 2.2 1.0
    Boric acid 0.0142 98 0.0139 61.8 0.23 0.1
    Xylene 15 ml 99 — — — —
  • A 50 ml three neck round bottom flask was fitted with a magnetic flea, thermometer, oil bath, condenser, and Dean & Stark apparatus filled with 3A molecular sieves 8-12 mesh (with 10 ml xylene). The system was purged with nitrogen and vented to atmosphere.
  • DF-Pyrazole acid (compound IV) (0.41 g), aniline (compound VII) (0.56 g), xylene (15 ml) and boric acid catalyst (14.2 mg) were charged to the flask. The mixture was heated to reflux (˜144 deg C.) and held on temperature for 8 hrs. Reaction was monitored via GCMS.
  • Conversion = 94 % conversion based on compound ( IV ) by GCMS = 54 % conversion based on compound ( VII ) by GCMS = 55 % conversion by NMR
  • GC/MS Details: The product had the same retention time, molecular ion (M+331) and fragmentation pattern as found with the authentic compound.
  • NMR: NMR spectrum of product was consistent with that for authentic material.
    • Example 5 Reaction Sequence
  • Figure US20120289707A1-20121115-C00030
  • A selection of catalysts (10 mol %) were screened. The procedure in Example 4 was repeated varying the catalyst employed.
  • Catalyst Solvent Connditions Results
    None Xylene Vigorous reflux 2% conversion to
    with Dean & desired product
    Stark set-up Relatively clean
    5 hr reaction
    B(OH)3 Xylene Vigorous reflux 55% conversion
    with Dean & to desired product
    Stark set-up Relatively clean
    8 hr reaction
    Figure US20120289707A1-20121115-C00031
         		Xylene Vigorous reflux with Dean & Stark set-up. 8 hr 55% conversion to the desired product
  • Conversions were determined by GCMS analysis. The results presented in the table are based on consumption of the aniline component. Conversions based on carboxylic acid consumption are different, presumably due to response factor differences. NMR analysis has shown that monitoring aniline consumption gives the best measure of reaction conversion.
  • Desired product was formed in all cases, but reaction rate was very slow without catalyst present. Reasonably good rates were achieved with both of the boron-based catalysts tried. Interestingly, a synthetically advantageous rate was achieved with cheap boric acid catalyst (55% conversion in 8 hr), The product was isolated and its structure confirmed by NMR analysis.
    • Example 6 Reaction Sequence
  • Figure US20120289707A1-20121115-C00032
  • Mo-
    Actual Strength 100% lecular Molar
    Materials Weight % Weight weight Mmol Ratio
    DF-Pyrazole 0.5 93.0 0.465 176 2.6 1.0
    acid (X)
    BiCP Aniline 0.94 48.7 0.458 173 2.6 1.0
    (XI)
    2-(N,N- 0.047 98 0.046 179 0.26 0.1
    dimethyl-
    aminomethyl)
    phenylboronic
    acid
    Xylene 20 ml 99 17.2 106 162 62.4
  • A 50 ml three neck round bottom flask was fitted with a magnetic flea, thermometer, oil bath, condenser, and Dean & Stark apparatus filled with 3 Å molecular sieves 8-12 mesh (with 10 ml xylene). The system was purged with nitrogen and vented to the atmosphere.
  • DF-pyrazole acid X (0.5 g), BiCP-aniline XI (0.94 g), xylene (20 ml) and 2-(N,N-dimethyl aminomethyl)phenylboronic acid catalyst (47 mg) were charged to the flask. The mixture was heated to reflux (˜143° C.) and held at this temperature for 10 hours.
  • The reaction was monitored via HPLC; 45% conversion being achieved after 5 hours, and 58% after 10 hours.
  • Product identity was confirmed by HPLC and GCMS comparison with authentic material.
    • Example 7 Reaction Sequence
  • Figure US20120289707A1-20121115-C00033
  • The procedure of Example 6 was repeated varying the catalyst employed.
  • Solvent Conditions Time Catalyst Conversion
    Xylene Reflux, Dean 5 hours None <1%
    and Stark
    Xylene Reflux, Dean 5 hours 2-(N,N- 45%
    and Stark dimethylaminomethyl)
    phenylboronic acid
    (10 Mol %)
    Xylene Reflux, Dean 5 hours Boric Acid 25%
    and Stark (10 Mol %)
    Xylene Reflux, Dean 20 hours  Boric Acid 50%
    and Stark (10 Mol %)
  • These results show that in the absence of catalysts, virtually no reaction occurred after 5 hours at 140° C.
  • Addition of catalyst, however, had a dramatic effect on reaction rate—45% conversion being achieved after 5 hours with 10% of 2-(N,N-dimethylaminomethyl) phenylboronic acid. Boric acid catalyst was less effective, but still generated a useful reaction rate (25% conversion after 5 hours). Product identity was confirmed by GCMS comparison with authentic material.

Claims (15)

1-16. (canceled)
17. A process for (a) the preparation of compounds of the formula (I)
Figure US20120289707A1-20121115-C00034
wherein
Het is pyrrolyl or pyrazolyl, either being substituted by groups R8, R9 and R10;
X is a single bond;
Y is (CR12R13)(CR14R15)m(CR16R17)n or C═C(A)Z in which A and Z are independently C1-6 alkyl or halogen;
m is 0 or 1;
n is 0 or 1;
R1 is hydrogen;
R2 and R3 are each, independently, hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy or C1-4 haloalkoxy;
R4, R5, R6 and R7 are each, independently, hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, hydroxymethyl, C1-4 alkoxymethyl, C(O)CH3 or C(O)OCH3;
R8, R9 and R10 are each, independently, hydrogen, halogen, cyano, nitro, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy(C1-4)alkylene or C1-4 haloalkoxy(C1-4)alkylene, provided that at least one of R8, R9 and R10 is not hydrogen;
R12 and R13 are each, independently, hydrogen, halogen, C1-5 alkyl, C1-3 alkoxy, CH2OH, CH(O), C3-6 cycloalkyl, CH2O—C(═O)CH3, CH2—C3-6 cycloalkyl or benzyl;
or R12 and R13 together with the carbon atom to which they are attached form the group C═O or a 3-5 membered carbocyclic ring;
or R12 and R13 together form C1-5 alkylidene or C3-6 cycloalkylidene; and
R14, R15, R16 and R17 are each, independently, H or CH3;
comprising the step of reacting a carboxylic acid of formula (II)
Figure US20120289707A1-20121115-C00035
wherein Het is as defined above
with an aniline of the formula (III)
Figure US20120289707A1-20121115-C00036
wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined above;
in the presence of a boronic acid catalyst or an antimony catalyst;
or (b) the preparation of compounds of the formula (IA)
Figure US20120289707A1-20121115-C00037
wherein
Heta is pyrrolyl, pyrazolyl or thiazolyl, each being substituted by groups R4a, R5a, R6a;
R1a is hydrogen, fluoro, chloro or bromo;
R2a is hydrogen, fluoro, chloro or bromo;
R3a is optionally substituted C2-12 alkyl, wherein, when present, each optional substituent is, independently, selected from fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H);
optionally substituted C2-12 alkenyl, wherein, when present, each optional substituent is, independently, selected from fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4-alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H);
optionally substituted C2-12 alkynyl, wherein, when present, each optional substituent is, independently, selected from fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H);
optionally substituted C3-12 cycloalkyl, wherein, when present, each optional substituent is, independently, selected from C1-3 alkyl, fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H); optionally substituted phenyl, wherein, when present, each optional substituent is, independently, selected from C1-6 alkyl, fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N and R′R″NN═C(H); or optionally substituted heterocyclyl, wherein, when present, each optional substituent is, independently, selected from C1-6 alkyl, fluoro, chloro, bromo, hydroxy, cyano, C1-4 alkoxyC(═O), formyl, nitro, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio, C1-4 haloalkylthio, HC(OR′)═N;
R′ and R″ are, independently, hydrogen or C1-4 alkyl; and
R4a, R5a, and R6a are, independently, selected from hydrogen, fluoro, chloro, bromo, cyano, nitro, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy(C1-4)alkyl and C1-4 haloalkoxy(C1-4)alkyl, provided that at least one of R4a, R5a, and R6a is not hydrogen.
comprising reacting a carboxylic acid of formula (IIA)
Figure US20120289707A1-20121115-C00038
with an aniline of the formula (IIIA)
Figure US20120289707A1-20121115-C00039
in the presence of a boronic acid catalyst or an antimony catalyst.
18. The process according to claim 1 wherein the boronic acid catalyst is an aryl boronic acid.
19. The process according to claim 1 wherein the boronic acid catalyst is 2-(N,N-dimethylaminomethyl)phenylboronic acid, boric acid or 3,5-trifluoromethylphenyl boronic acid.
20. The process according to claim 1 wherein the antimony catalyst is Sb(OEt)3.
21. The process according to claim 1 wherein the catalyst is employed in an amount of between 1 and 15 mol % based on the amount of carboxylic acid (II) or (IIA).
22. The process according to claim 1 wherein the catalyst is employed in an amount of between 1 and 15 mol % based on the amount of aniline (III) or (IIIA).
23. The process according to claim 1 wherein the molar ratio of acid (II) or (IIA):aniline (III) or (IIIA) is in the range of from 2:1 to 1:2.
24. The process according to claim 1 wherein Het is a group of formula (VIIA)
Figure US20120289707A1-20121115-C00040
in which R7a is selected from CF3 and CHF2;
and/or wherein Y is CHCH(CH3)CH3 or C═CCl2;
and/or wherein R2, R3, R4, R5, R6, R7 are independently selected from hydrogen.
25. The process according to claim 1 wherein Y is CHCH(CH3)CH3.
26. The process according to claim 1 wherein Y is C═CCl2.
27. A process according to claim 1 for the preparation of a compound of formula (VI)
Figure US20120289707A1-20121115-C00041
comprising reacting a carboxylic acid of formula (IV)
Figure US20120289707A1-20121115-C00042
with an aniline of formula (V)
Figure US20120289707A1-20121115-C00043
in the presence of a boronic acid catalyst or an antimony catalyst.
28. A process according to claim 1 for the preparation of a compound of formula (VIII)
Figure US20120289707A1-20121115-C00044
comprising reacting a carboxylic acid of formula (IV)
Figure US20120289707A1-20121115-C00045
with an aniline of formula (VII)
Figure US20120289707A1-20121115-C00046
in the presence of a boronic acid catalyst or an antimony catalyst.
29. The process according to claim 1, wherein Heta is a group of formula (VIIA)
Figure US20120289707A1-20121115-C00047
in which R7a is selected from CF3 and CHF2;
and/or wherein R3a is a group of the formula (VIIIA)
Figure US20120289707A1-20121115-C00048
in which R8 is H or C1-6 alkyl.
30. A process according to claim 1 for the preparation of a compound of formula (IXA)
Figure US20120289707A1-20121115-C00049
comprising reacting a carboxylic acid of formula (IV)
Figure US20120289707A1-20121115-C00050
with an aniline of formula (XIA)
Figure US20120289707A1-20121115-C00051
in the presence of a boronic acid catalyst or an antimony catalyst.
US13/556,904 2008-05-14 2012-07-24 Process for the preparation of amides Abandoned US20120289707A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/556,904 US20120289707A1 (en) 2008-05-14 2012-07-24 Process for the preparation of amides

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0808772A GB0808772D0 (en) 2008-05-14 2008-05-14 Process
GB0808766.0 2008-05-14
GB0808766A GB0808766D0 (en) 2008-05-14 2008-05-14 Process
GB0808772.8 2008-05-14
PCT/EP2009/055651 WO2009138375A1 (en) 2008-05-14 2009-05-11 Process for the preparation of amides
US99278111A 2011-02-21 2011-02-21
US13/556,904 US20120289707A1 (en) 2008-05-14 2012-07-24 Process for the preparation of amides

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2009/055651 Continuation WO2009138375A1 (en) 2008-05-14 2009-05-11 Process for the preparation of amides
US99278111A Continuation 2008-05-14 2011-02-21

Publications (1)

Publication Number Publication Date
US20120289707A1 true US20120289707A1 (en) 2012-11-15

Family

ID=40972905

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/992,781 Expired - Fee Related US8227619B2 (en) 2008-05-14 2009-05-11 Process for the preparation of amides
US13/556,904 Abandoned US20120289707A1 (en) 2008-05-14 2012-07-24 Process for the preparation of amides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/992,781 Expired - Fee Related US8227619B2 (en) 2008-05-14 2009-05-11 Process for the preparation of amides

Country Status (9)

Country Link
US (2) US8227619B2 (en)
EP (1) EP2280944A1 (en)
JP (1) JP2011520828A (en)
CN (1) CN102026982A (en)
BR (1) BRPI0912558A2 (en)
IL (1) IL208792A0 (en)
MX (1) MX2010011790A (en)
TW (1) TW200950701A (en)
WO (1) WO2009138375A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2181087B1 (en) 2007-08-16 2015-10-14 Solvay Sa Process for the preparation of esters of 4-fluorosubstituted 3-oxo-alcanoic acids
GB201004301D0 (en) * 2010-03-15 2010-04-28 Syngenta Participations Ag Process
EP2560960B1 (en) * 2010-04-20 2014-02-26 Syngenta Participations AG Process for the preparation of pyrazole carboxylic acid amides
US8987470B2 (en) 2010-10-27 2015-03-24 Solvay Sa Process for the preparation of pyrazole-4-carboxamides
TWI534126B (en) * 2011-01-25 2016-05-21 先正達合夥公司 Process for the preparation of pyrazole carboxylic acid amides
EP2675816A4 (en) * 2011-02-14 2014-08-13 Univ Alberta Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids
WO2013118130A1 (en) * 2012-02-06 2013-08-15 Symed Labs Limited A process for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene carboxamide
CN105557722A (en) * 2014-10-15 2016-05-11 陕西美邦农药有限公司 Pesticide composition containing benzovindiflupyr
WO2017054112A1 (en) * 2015-09-28 2017-04-06 常州市卜弋科研化工有限公司 Method of preparing 3-fluoroalkyl-1-methylpyrazole-4-carboxylic acid
CN106588745B (en) * 2016-12-02 2019-06-14 杭州百昂锐地科技有限公司 A kind of intermediate and its preparation method and application of benzo alkene fluorine bacterium azoles
CN115947688B (en) * 2023-03-15 2023-05-16 佛山职业技术学院 Pyrazolonamine hapten, antigen, antibody, detection device and preparation and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035589A1 (en) * 2002-10-18 2004-04-29 Syngenta Participations Ag Heterocyclocarboxamide derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763234A (en) * 1970-12-03 1973-10-02 Halcon International Inc Preparation of amides
MXPA04008314A (en) * 2002-03-05 2004-11-26 Syngenta Participations Ag O-cyclopropyl-carboxanilides and their use as fungicides.
GB0322012D0 (en) * 2003-09-19 2003-10-22 Syngenta Participations Ag Chemical compounds
ES2397932T3 (en) * 2005-09-16 2013-03-12 Syngenta Participations Ag Procedure for the production of amides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035589A1 (en) * 2002-10-18 2004-04-29 Syngenta Participations Ag Heterocyclocarboxamide derivatives

Also Published As

Publication number Publication date
JP2011520828A (en) 2011-07-21
WO2009138375A1 (en) 2009-11-19
IL208792A0 (en) 2010-12-30
CN102026982A (en) 2011-04-20
US20110178310A1 (en) 2011-07-21
BRPI0912558A2 (en) 2015-07-28
US8227619B2 (en) 2012-07-24
TW200950701A (en) 2009-12-16
MX2010011790A (en) 2010-11-25
EP2280944A1 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
US8227619B2 (en) Process for the preparation of amides
US9051272B2 (en) Process for the preparation of phenyl substituted 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid N-methoxy-[1-methyl-2 phenylethyl] amides
US8563748B2 (en) Process for preparing substituted N-phenylhydroxylamines
CA2035978A1 (en) Hetarylalkenes, their preparation and intermediates for their preparation, and their use
TW201619139A (en) Process for the preparation of 5-fluoro-1H-pyrazoles starting from hexafluoropropene
WO2009003650A1 (en) Preparation of biaryls
JPS6258355B2 (en)
US8501993B2 (en) Processes for the preparation of amides
EP2257530B1 (en) Process for preparing substituted biphenylanilides
US20110263889A1 (en) Processes for the preparation of esters
US5059615A (en) Antimycotically active cyclopropyl-substituted azolylmethylcarbinols
US7102046B2 (en) Process for the arylation of olefins
EP3099658B1 (en) Process of production of 2,3,6-trimethylphenol
SAKAMOTO et al. Studies on Pyrimidine Derivatives. XXX. The Palladium-Catalyzed Cross-Coupling Reaction of Iodopyrimidines with Terminal Olefinic Compounds
EP1346971B1 (en) Production method for biarylalanine
CN109438288A (en) A kind of N- nitrone substituted aroma amide derivatives and preparation method thereof
US20040054194A1 (en) Method for producing 1-pyrrolines
CN103254132B (en) One prepares the method for the pyrazoline derivative that 1,3,5-triaryl replaces
US9604933B2 (en) Pyrazolochalcones as potential anticancer agents
坂本尚夫 et al. Studies on pyrimidine derivatives. XXX. The palladium-catalyzed cross-coupling reaction of iodopyrimidines with terminal olefinic compounds.
WO2020094440A1 (en) Process for the synthesis of aryl hydrazines
CN107805218A (en) A kind of method for preparing 4 Boc amino piperidines
Huang Asymmetric [4+ 3] cycloadditions via epoxidation of allenamides
JPH06172311A (en) Novel diamine compounds and their production
KR20110086014A (en) Method for producing oxadiazolinone compound and intermediate thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE